Reuters logo
in 12 days
BRIEF-Morphosys CEO sees 5 months of guselkumab royalties this year
July 14, 2017 / 9:24 AM / in 12 days

BRIEF-Morphosys CEO sees 5 months of guselkumab royalties this year

1 Min Read

July 14 (Reuters) - Morphosys CEO tells Reuters

* Says he expects royalties for 5 months this year after U.S. Approval of guselkumab

* Says milestone payment for guselkumab approval is included in FY guidance, royalties are not Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below